139 related articles for article (PubMed ID: 12883036)
1. Enhancement of platinum-induced cytotoxicity by O6-benzylguanine.
Fishel ML; Delaney SM; Friesen LD; Hansen RJ; Zuhowski EG; Moschel RC; Egorin MJ; Dolan ME
Mol Cancer Ther; 2003 Jul; 2(7):633-40. PubMed ID: 12883036
[TBL] [Abstract][Full Text] [Related]
2. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
Cai Y; Wu MH; Xu-Welliver M; Pegg AE; Ludeman SM; Dolan ME
Cancer Res; 2000 Oct; 60(19):5464-9. PubMed ID: 11034089
[TBL] [Abstract][Full Text] [Related]
3. Effect of O6-benzylguanine on nitrogen mustard-induced toxicity, apoptosis, and mutagenicity in Chinese hamster ovary cells.
Cai Y; Ludeman SM; Wilson LR; Chung AB; Dolan ME
Mol Cancer Ther; 2001 Nov; 1(1):21-8. PubMed ID: 12467235
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
Liu L; Schwartz S; Davis BM; Gerson SL
Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
[TBL] [Abstract][Full Text] [Related]
5. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine.
Loktionova NA; Xu-Welliver M; Crone TM; Kanugula S; Pegg AE
Biochem Pharmacol; 1999 Jul; 58(2):237-44. PubMed ID: 10423163
[TBL] [Abstract][Full Text] [Related]
6. Role of GADD34 in modulation of cisplatin cytotoxicity.
Fishel ML; Rabik CA; Bleibel WK; Li X; Moschel RC; Dolan ME
Biochem Pharmacol; 2006 Jan; 71(3):239-47. PubMed ID: 16325149
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.
Wedge SR; Porteus JK; May BL; Newlands ES
Br J Cancer; 1996 Feb; 73(4):482-90. PubMed ID: 8595163
[TBL] [Abstract][Full Text] [Related]
8. Selective enhancement of ifosfamide-induced toxicity in Chinese hamster ovary cells.
Smith SM; Ludeman SM; Wilson LR; Springer JB; Gandhi MC; Dolan ME
Cancer Chemother Pharmacol; 2003 Oct; 52(4):291-302. PubMed ID: 12845477
[TBL] [Abstract][Full Text] [Related]
9. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents.
Dolan ME; Mitchell RB; Mummert C; Moschel RC; Pegg AE
Cancer Res; 1991 Jul; 51(13):3367-72. PubMed ID: 1647266
[TBL] [Abstract][Full Text] [Related]
10. Acquired resistance to O6-benzylguanine plus chloroethylnitrosoureas in human breast cancer.
Phillips WP; Gerson SL
Cancer Chemother Pharmacol; 1999; 44(4):319-26. PubMed ID: 10447580
[TBL] [Abstract][Full Text] [Related]
11. Expression of mammalian O6-alkylguanine-DNA alkyltransferase in a cell line sensitive to alkylating agents.
Dolan ME; Norbeck L; Clyde C; Hora NK; Erickson LC; Pegg AE
Carcinogenesis; 1989 Sep; 10(9):1613-9. PubMed ID: 2766456
[TBL] [Abstract][Full Text] [Related]
12. Differential sensitivity of human and mouse alkyltransferase to O6-benzylguanine using a transgenic model.
Liu L; Lee K; Wasan E; Gerson SL
Cancer Res; 1996 Apr; 56(8):1880-5. PubMed ID: 8620508
[TBL] [Abstract][Full Text] [Related]
13. Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity.
Fishel ML; Newell DR; Griffin RJ; Davison R; Wang LZ; Curtin NJ; Zuhowski EG; Kasza K; Egorin MJ; Moschel RC; Dolan ME
J Pharmacol Exp Ther; 2005 Jan; 312(1):206-13. PubMed ID: 15304523
[TBL] [Abstract][Full Text] [Related]
14. Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase.
Friedman HS; Pegg AE; Johnson SP; Loktionova NA; Dolan ME; Modrich P; Moschel RC; Struck R; Brent TP; Ludeman S; Bullock N; Kilborn C; Keir S; Dong Q; Bigner DD; Colvin OM
Cancer Chemother Pharmacol; 1999; 43(1):80-5. PubMed ID: 9923545
[TBL] [Abstract][Full Text] [Related]
15. The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation.
Baumann RP; Seow HA; Shyam K; Penketh PG; Sartorelli AC
Oncol Res; 2005; 15(6):313-25. PubMed ID: 16408696
[TBL] [Abstract][Full Text] [Related]
16. Conserved residue lysine165 is essential for the ability of O6-alkylguanine-DNA alkyltransferase to react with O6-benzylguanine.
Xu-Welliver M; Kanugula S; Loktionova NA; Crone TM; Pegg AE
Biochem J; 2000 Apr; 347(Pt 2):527-34. PubMed ID: 10749683
[TBL] [Abstract][Full Text] [Related]
17. Point mutations in human O6-alkylguanine-DNA alkyltransferase prevent the sensitization by O6-benzylguanine to killing by N,N'-bis (2-chloroethyl)-N-nitrosourea.
Loktionova NA; Pegg AE
Cancer Res; 1996 Apr; 56(7):1578-83. PubMed ID: 8603405
[TBL] [Abstract][Full Text] [Related]
18. Role of codon 160 in the sensitivity of human O6-alkylguanine-DNA alkyltransferase to O6-benzylguanine.
Xu-Welliver M; Leitão J; Kanugula S; Meehan WJ; Pegg AE
Biochem Pharmacol; 1999 Oct; 58(8):1279-85. PubMed ID: 10487529
[TBL] [Abstract][Full Text] [Related]
19. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
Wedge SR; Porteous JK; Newlands ES
Br J Cancer; 1996 Oct; 74(7):1030-6. PubMed ID: 8855970
[TBL] [Abstract][Full Text] [Related]
20. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.
Dolan ME; Posner M; Karrison T; Radosta J; Steinberg G; Bertucci D; Vujasin L; Ratain MJ
Clin Cancer Res; 2002 Aug; 8(8):2519-23. PubMed ID: 12171878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
